Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells-Reference-Cited by-同舟云学术

Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells

Published:2019-12-05 Issue:12 Volume:14 Page:e0226154
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Shimano Kyoko,Maeda Yasuhiro,Kataoka Hirotoshi,Murase Mikako,Mochizuki Sachiko,Utsumi Hiroyuki,Oshita Koichi,Sugahara Kunio^ORCID

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference29 articles.

1. Inflammatory bowel disease: the role of environmental factors;S Danese;Autoimmun Rev,2004

2. Inflammatory bowel disease: cause and immunobiology;DC Baumgart;Lancet,2007

3. T-cell function and migration. Two sides of the same coin;UH von Andrian;N Engl J Med,2000

4. Cell trafficking interference in inflammatory bowel disease: Therapeutic interventions based on basic pathogenesis concepts;T Pérez-Jeldres;Inflamm Bowel Dis,2019

5. Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk;K Sugahara;Br J Pharmacol,2017

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sphingosine-1-phosphate signaling regulates the ability of Müller glia to become neurogenic, proliferating progenitor-like cells;2024-08-06

2. A reverse translational approach reveals the protective roles of Mangifera indica in inflammatory bowel disease;Journal of Autoimmunity;2024-04

3. Oral small molecule agents in management of ulcerative colitis: fact or fancy;Turkish Journal of Medical Sciences;2023-12-12

4. Structure, function and drug discovery of GPCR signaling;Molecular Biomedicine;2023-12-04

5. A Randomized, Double‐Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers;Clinical Pharmacology in Drug Development;2023-01-28